Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type

[1] Peh SC(2001)Host ethnicity influences non-Hodgkin’s lymphoma subtype frequency and Epstein–Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia Histopathology 38 458-465

[2] Kwong YL(2009)Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Lancet Oncol 10 1093-1101

[3] Anderson BO(2007)The role of FDG-PET scans in patients with lymphoma Blood 110 3507-3516

[4] Advani R(2013)Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma Eur J Nucl Med Mol Imaging 40 1321-1329

[5] Kim WS(2014)Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center J Nucl Med 55 911-916

[6] Levine AM(2009)Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 11S-20S

[7] Lim ST(2011)18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation J Nucl Med 52 386-392

[8] Seam P(2007)Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma J Clin Oncol 25 571-578

[9] Juweid ME(1999)Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244-515

[10] Cheson BD(2013)Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas J Nucl Med 54 507-800

[1] Peh SC(2001)Host ethnicity influences non-Hodgkin’s lymphoma subtype frequency and Epstein–Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia Histopathology 38 458-465

[2] Kwong YL(2009)Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Lancet Oncol 10 1093-1101

[3] Anderson BO(2007)The role of FDG-PET scans in patients with lymphoma Blood 110 3507-3516

[4] Advani R(2013)Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma Eur J Nucl Med Mol Imaging 40 1321-1329

[5] Kim WS(2014)Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center J Nucl Med 55 911-916

[6] Levine AM(2009)Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 11S-20S

[7] Lim ST(2011)18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation J Nucl Med 52 386-392

[8] Seam P(2007)Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma J Clin Oncol 25 571-578

[9] Juweid ME(1999)Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244-515

[10] Cheson BD(2013)Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas J Nucl Med 54 507-800